Additional file 1 of Screening helper T lymphocyte epitopes based on IFN-γ/IL-10 ratio for developing a novel multi-epitope vaccine candidate using Wolbachia surface protein as an adjuvant against visceral leishmaniasis

Additional File 1: Supplementary Table S1. The IEDB input sequences of HbR, KMP-11, Gp63, TSA, and SMT for HTL epitope prediction; Supplementary Table S2. The HTL epitopes of HbR, KMP-11, Gp63, TSA, and SMT identified by IEDB; Supplementary Table S3. The original HTL prediction results of HbR, KMP-11, Gp63, TSA, and SMT identified by IEDB; Supplementary Table S4. The IEDB input sequences of HbR, KMP-11, Gp63, TSA, and SMT for CTL epitope prediction; Supplementary Table S5. The CTL epitopes of HbR, KMP-11, Gp63, TSA, and SMT identified by IEDB; Supplementary Table S6. The original CTL prediction results of HbR, KMP-11, Gp63, TSA, and SMT identified by IEDB. Supplementary Table S7. HTL epitopes with antigenicity indices > 0.5, nontoxic and non-allergenic properties, and IFN-γ-inducing epitope potential from HbR, KMP-11, Gp63, TSA, and SMT; Supplementary Table S8. Antigenicity, allergenicity, toxicity, and IFN-g-inducing epitope potential analysis results from HTL epitopes; Supplementary Table S9. Non-allergenic and non-toxic CTL epitopes with antigenicity index > 0.5 from HbR, KMP-11, Gp63, TSA, and SMT; Supplementary Table S10. Antigenicity, allergenicity, and toxicity analysis results from CTL epitopes; Supplementary Table S11. Coverage of epitopes from the vaccine candidate recognized by HLA alleles/The distribution of HLA I and HLA II alleles recognizing epitopes in the world; Supplementary Table S12. The interfaces between TLRs and vaccine candidate.